Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: Propensity score analysis

BMC Gastroenterology

Volumn 14, Issue 1, 2014, Pages

  Nakazawa, Takahide ^a,b   Hidaka, Hisashi ^a   Shibuya, Akitaka ^a   Okuwaki, Yusuke ^a   Tanaka, Yoshiaki ^a   Takada, Juichi ^a   Minamino, Tsutomu ^a   Watanabe, Masaaki ^a   Kokubu, Shigehiro ^c   Koizumi, Wasaburo ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Nakazawa Medical Clinic   (Japan)

^c JUNTENDO UNIVERSITY NERIMA HOSPITAL   (Japan)

Author keywords

Hepatocellular carcinoma; Overall survival; Portal venous tumor thrombosis; Radiotherapy; Sorafenib

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD PUGH SCORE; CONTROLLED STUDY; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; JAPAN; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PANCREATITIS; PORTAL VEIN THROMBOSIS; PROPENSITY SCORE; PROTEINURIA; RADIATION DOSE; RETROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR INVASION; TUMOR THROMBUS; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; COHORT ANALYSIS; COMPARATIVE STUDY; COMPLICATION; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PORTAL VEIN; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RADIOTHERAPY; SURVIVAL RATE; TREATMENT OUTCOME; VENOUS THROMBOSIS;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PORTAL VEIN; PROGNOSIS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 84900308309     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-14-84     Document Type: Article

References (28)

1. Poon R, Fan S, Lo C, Wang J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 1999, 229:216-222. 10.1097/00000658-199902000-00009, 1191634, 10024103.
2. Nakazawa T, Kokubu S, Shibuya A, Ono K, Watanabe M, Hidaka H, Tsuchihashi T, Saigenji K. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. Am J Roentgenol 2007, 188:480-488.
3. Okuwaki Y, Nakazawa T, Shibuya A, Ono K, Hidaka H, Watanabe M, Kokubu S, Saigenji K. Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: Risk factors and patterns. J Gastroenterol 2008, 43:71-78. 10.1007/s00535-007-2123-z, 18297439.
4. Okuwaki Y, Nakazawa T, Kokubu S, Hidaka H, Tanaka Y, Takada J, Watanabe M, Shibuya A, Minamino T, Saigenji K. Repeat radiofrequency ablation provides survival benefit in patients with intrahepatic distant recurrence of hepatocellular carcinoma. Am J Gastroenterol 2009, 104:2747-2753. 10.1038/ajg.2009.414, 19603009.
5. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Brú C, Rodés J, Bruix J. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999, 29:62-67. 10.1002/hep.510290145, 9862851.
6. Schöniger-Hekele M, Müller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut 2001, 48:103-109. 10.1136/gut.48.1.103, 1728163, 11115830.
7. Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol 2006, 12:7561-7567.
8. Nakazawa T, Adachi S, Kitano M, Isobe Y, Kokubu S, Hidaka H, Ono K, Okuwaki Y, Watanabe M, Shibuya A, Saigenji K. Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels. Oncology 2007, 73:90-97. 10.1159/000120996, 18337620.
9. Lau WY, Sangro B, Chen PJ, Cheng SQ, Chow P, Lee RC, Leung T, Han KH, Poon RT. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology 2013, 84:311-318. 10.1159/000348325, 23615394.
10. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002, 95:588-595. 10.1002/cncr.10694, 12209752.
11. Ota H, Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Nakamura M, Damdinsuren B, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Wakasa K, Monden M. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005, 93:557-564. 10.1038/sj.bjc.6602742, 2361594, 16106266.
12. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, . SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390. 10.1056/NEJMoa0708857, 18650514, SHARP Investigators Study Group.
13. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34. 10.1016/S1470-2045(08)70285-7, 19095497.
14. Nakazawa T, Hidaka H, Takada J, Okuwaki Y, Tanaka Y, Watanabe M, Shibuya A, Minamino T, Kokubu S, Koizumi W. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 2013, 25:683-689. 10.1097/MEG.0b013e32835d913b, 23395995.
15. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109. 10.1158/0008-5472.CAN-04-1443, 15466206.
16. Xi M, Zhang L, Zhao L, Li QQ, Guo SP, Feng ZZ, Deng XW, Huang XY, Liu MZ. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One 2013, 8:e63864. 10.1371/journal.pone.0063864, 3667854, 23737955.
17. Tanaka Y, Nakazawa T, Komori S, Hidaka H, Okuwaki Y, Takada J, Watanabe M, Shibuya A, Minamino T, Yamamoto H, Kokubu S, Hayakawa K, Koizumi W. Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels: efficacy and outcomes. J Gastroenterol Hepatol 2014, 29:352-357. 10.1111/jgh.12333, 23869689.
18. Murakami E, Aikata H, Miyaki D, Nagaoki Y, Katamura Y, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Takahashi S, Kimura T, Kenjo M, Nagata Y, Ishikawa M, Kakizawa H, Awai K, Chayama K. Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon-α for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava. Hepatol Res 2012, 42:442-453. 10.1111/j.1872-034X.2011.00943.x, 22176468.
19. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247. 10.1016/j.ejca.2008.10.026, 19097774.
20. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010, 30:52-60. 10.1055/s-0030-1247132, 20175033.
21. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol 1982, 5:649-655. 10.1097/00000421-198212000-00014, 7165009.
22. Guo S, Fraser MW. Propensity Score Analysis: Statistical Methods and Applications. Advanced Quantitative Techniques in the Social Sciences Series; v. 12 2010, Los Angeles: SAGE Publications, Inc.
23. Pirisi M, Avellini C, Fabris C, Scott C, Bardus P, Soardo G, Beltrami CA, Bartoli E. Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study. J Cancer Res Clin Oncol 1998, 124:397-400. 10.1007/s004320050189, 9719503.
24. Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, Shin YM, Kim KM, Lim YS, Lee HC. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology 2013, 269:603-611. 10.1148/radiol.13130150, 23864102.
25. Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, Shums Z, Aoki T, Hasegawa K, Beck Y, Sugawara Y, Kokudo N. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol 2010, 45:1272-1282. 10.1007/s00535-010-0278-5, 20625772.
26. Liu L, Zhao Y, Qi X, Cai G, He C, Guo W, Yin Z, Chen H, Chen X, Fan D, Han G. Transjugular intrahepatic portosystemic shunt for symptomatic portal hypertension in hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol Res 2013, doi:10.1111/hepr.12162. [Epub ahead of print].
27. Hidaka H, Nakazawa T, Kaneko T, Minamino T, Takada J, Tanaka Y, Okuwaki Y, Watanabe M, Shibuya A, Koizumi W. Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study. J Gastroenterol 2012, 47:1030-1035. 10.1007/s00535-012-0563-6, 22402773.
28. Coriat R, Gouya H, Mir O, Ropert S, Vignaux O, Chaussade S, Sogni P, Pol S, Blanchet B, Legmann P, Goldwasser F. Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. PLoS One 2011, 6:e16978. 10.1371/journal.pone.0016978, 3038868, 21340026.